- Home
- LINC vs TSHA Comparison
LINC vs TSHA Comparison
Compare LINC & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LINC | TSHA |
|---|---|---|
| Founded | 1946 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.2B |
| IPO Year | 2005 | 2020 |
Fundamental Metrics
Financial Performance| Metric | LINC | TSHA |
|---|---|---|
| Price | $37.48 | $4.40 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 9 |
| Target Price | ★ $37.50 | $10.78 |
| AVG Volume (30 Days) | 610.4K | ★ 2.3M |
| Earning Date | 02-23-2026 | 03-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 100.00 | 5.56 |
| EPS | ★ 0.64 | N/A |
| Revenue | ★ $261,853,000.00 | $9,773,000.00 |
| Revenue This Year | $14.82 | N/A |
| Revenue Next Year | $8.13 | $637.76 |
| P/E Ratio | $60.05 | ★ N/A |
| Revenue Growth | ★ 32.98 | 17.28 |
| 52 Week Low | $14.84 | $1.13 |
| 52 Week High | $41.48 | $6.02 |
Technical Indicators
Market Signals| Indicator | LINC | TSHA |
|---|---|---|
| Relative Strength Index (RSI) | 63.03 | 41.76 |
| Support Level | $21.46 | $4.03 |
| Resistance Level | $37.85 | $4.72 |
| Average True Range (ATR) | 1.98 | 0.21 |
| MACD | -0.18 | -0.00 |
| Stochastic Oscillator | 43.15 | 18.07 |
Price Performance
Historical ComparisonAbout LINC Lincoln Educational Services Corporation
Lincoln Educational Services Corp provides diversified career-oriented post-secondary education to high school graduates and working adults. The company offers programs in automotive technology, skilled trades, healthcare services, hospitality services, and business and information technology. Its reportable segments include: Campus Operations and Transitional. The majority of the revenue is generated from the Campus Operations segment, which includes all campuses that are continuing in operation and contribute to the company's core operations and performance.
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.